| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A comparison of matched interim analysis publications and final analysis publications in oncology clinical trials
|
Wayant, C.
|
|
|
29 |
12 |
p. 2384-2390
|
article
|
| 2 |
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial
|
Smyth, E.C.
|
|
|
29 |
12 |
p. 2356-2362
|
article
|
| 3 |
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
|
Gross-Goupil, M.
|
|
|
29 |
12 |
p. 2371-2378
|
article
|
| 4 |
Can estrogen receptor status predict for shorter duration of adjuvant trastuzumab in early-stage breast cancer?
|
Mathew, A.
|
|
|
29 |
12 |
p. 2391-2392
|
article
|
| 5 |
Carboplatin in the neoadjuvant treatment of triple-negative breast cancer—ready for prime time?
|
Foukakis, T.
|
|
|
29 |
12 |
p. 2278-2280
|
article
|
| 6 |
CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?
|
Brandão, M.
|
|
|
29 |
12 |
p. 2274-2278
|
article
|
| 7 |
Comment on ‘Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy’
|
Brentisci, C.
|
|
|
29 |
12 |
p. 2395-2396
|
article
|
| 8 |
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016
|
Marandino, L.
|
|
|
29 |
12 |
p. 2288-2295
|
article
|
| 9 |
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
|
Ciavarella, S.
|
|
|
29 |
12 |
p. 2363-2370
|
article
|
| 10 |
Duration of adjuvant trastuzumab: might less be more?
|
Metzger Filho, O.
|
|
|
29 |
12 |
p. 2273-2274
|
article
|
| 11 |
Editorial Board
|
|
|
|
29 |
12 |
p. ii-iii
|
article
|
| 12 |
Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing
|
Zhu, Y.C.
|
|
|
29 |
12 |
p. 2392-2393
|
article
|
| 13 |
Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials
|
Sen, S.
|
|
|
29 |
12 |
p. 2396-2398
|
article
|
| 14 |
KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer
|
Montagut, C.
|
|
|
29 |
12 |
p. 2280-2282
|
article
|
| 15 |
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
|
Cottu, P.
|
|
|
29 |
12 |
p. 2334-2340
|
article
|
| 16 |
More accurate prognostic prediction in diffuse large B-cell lymphoma: beyond cell-of-origin
|
Koya, J.
|
|
|
29 |
12 |
p. 2284-2286
|
article
|
| 17 |
Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer
|
Wan, Y.
|
|
|
29 |
12 |
p. 2379-2383
|
article
|
| 18 |
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study ‡
|
Conte, P.
|
|
|
29 |
12 |
p. 2328-2333
|
article
|
| 19 |
Novel therapies in urothelial carcinoma: a biomarker-driven approach
|
Iyer, G.
|
|
|
29 |
12 |
p. 2302-2312
|
article
|
| 20 |
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach
|
Galot, R.
|
|
|
29 |
12 |
p. 2313-2327
|
article
|
| 21 |
Quality of life assessment using patient-reported outcome (PRO) measures: still a Cinderella outcome?
|
Fallowfield, L.J.
|
|
|
29 |
12 |
p. 2286-2287
|
article
|
| 22 |
Repeated mut KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer
|
Kruger, S.
|
|
|
29 |
12 |
p. 2348-2355
|
article
|
| 23 |
Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study
|
Hobbs, B.P.
|
|
|
29 |
12 |
p. 2296-2301
|
article
|
| 24 |
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
|
Loibl, S.
|
|
|
29 |
12 |
p. 2341-2347
|
article
|
| 25 |
Table of Contents
|
|
|
|
29 |
12 |
p. iv-v
|
article
|
| 26 |
Towards risk-adapted perioperative treatment of gastroesophageal cancer
|
Lordick, F.
|
|
|
29 |
12 |
p. 2282-2284
|
article
|
| 27 |
Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial
|
Gaiser, M.R.
|
|
|
29 |
12 |
p. 2393-2395
|
article
|
Journal description